Linezolid-associated peripheral neuropathy

Jennifer P. Rho, Irene Gaw Sia, Brian A. Crum, Mark B. Dekutoski, Robert T. Trousdale

Research output: Contribution to journalArticle

58 Scopus citations


Linezolid is the first drug in a new class of synthetic antimicrobials, the oxazolidinones, to be approved by the Food and Drug Administration. Linezolid is active against methicillin- and vancomycin-resistant gram-positive microorganisms. We describe 2 patients who developed peripheral neuropathy after prolonged treatment with linezolid. Linezolid-associated peripheral neuropathy has not been well documented. Most reported cases of linezolid-associated peripheral neuropathy have occurred in patients who took linezolid for a period longer than the recommended 28 or fewer days. Health care providers must be alert to the potential for serious adverse effects associated with linezolid use, including peripheral neuropathy.

Original languageEnglish (US)
Pages (from-to)927-930
Number of pages4
JournalMayo Clinic Proceedings
Issue number7
StatePublished - 2004


ASJC Scopus subject areas

  • Medicine(all)

Cite this

Rho, J. P., Sia, I. G., Crum, B. A., Dekutoski, M. B., & Trousdale, R. T. (2004). Linezolid-associated peripheral neuropathy. Mayo Clinic Proceedings, 79(7), 927-930.